Peptide Graded

Efpeglenatide

Is Efpeglenatide safe?

Trial safety for about 1.8 years

BSome human evidenceIn clinical trialsas of 2026-10-27

Side effects in AMPLITUDE-O matched the GLP-1 class. Nausea, diarrhea and vomiting were more common than with placebo. More participants on efpeglenatide stopped treatment because of gut problems. Serious adverse events were not significantly more frequent than placebo. Neither were severe hypoglycemia, pancreatitis or retinopathy events. No one collected safety data beyond two years. Sanofi stopped development. 2

Read the full Efpeglenatide page

More on Efpeglenatide

Citations

  1. StatPearls: glucagon-like peptide-1 receptor agonists ncbi.nlm.nih.gov
  2. Gerstein 2021, NEJM: cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (AMPLITUDE-O) doi.org
  3. Lam 2021, Circulation: efpeglenatide and clinical outcomes with and without concomitant SGLT2 inhibitor use doi.org
  4. South Korea MFDS: efpeglenatide (Efe) approval notice, October 2026 mfds.go.kr

Reference information only, not medical advice. Drawn from the Efpeglenatide article, fact-checked against the cited sources. No dosing anywhere on this site.